JP2011157399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011157399A5 JP2011157399A5 JP2011112835A JP2011112835A JP2011157399A5 JP 2011157399 A5 JP2011157399 A5 JP 2011157399A5 JP 2011112835 A JP2011112835 A JP 2011112835A JP 2011112835 A JP2011112835 A JP 2011112835A JP 2011157399 A5 JP2011157399 A5 JP 2011157399A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- virus
- myxoma virus
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 241000700562 Myxoma virus Species 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 201000011510 cancer Diseases 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 15
- 208000036142 Viral infection Diseases 0.000 claims 12
- 230000009385 viral infection Effects 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000037581 Persistent Infection Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 210000005260 human cell Anatomy 0.000 claims 8
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000002035 prolonged effect Effects 0.000 claims 8
- 230000002085 persistent effect Effects 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 5
- 108010050904 Interferons Proteins 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45252103P | 2003-03-07 | 2003-03-07 | |
| US60/452,521 | 2003-03-07 | ||
| US45539303P | 2003-03-18 | 2003-03-18 | |
| US60/455,393 | 2003-03-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504071A Division JP4800924B2 (ja) | 2003-03-07 | 2004-03-08 | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011157399A JP2011157399A (ja) | 2011-08-18 |
| JP2011157399A5 true JP2011157399A5 (https=) | 2011-10-06 |
Family
ID=32965588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504071A Expired - Fee Related JP4800924B2 (ja) | 2003-03-07 | 2004-03-08 | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
| JP2011112835A Withdrawn JP2011157399A (ja) | 2003-03-07 | 2011-05-19 | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504071A Expired - Fee Related JP4800924B2 (ja) | 2003-03-07 | 2004-03-08 | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7582614B2 (https=) |
| EP (1) | EP1601376B1 (https=) |
| JP (2) | JP4800924B2 (https=) |
| KR (1) | KR101116858B1 (https=) |
| AU (1) | AU2004216928C1 (https=) |
| CA (1) | CA2517147C (https=) |
| IL (1) | IL170601A (https=) |
| MX (1) | MXPA05009526A (https=) |
| NZ (1) | NZ541951A (https=) |
| RU (1) | RU2362584C2 (https=) |
| WO (1) | WO2004078206A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4800924B2 (ja) * | 2003-03-07 | 2011-10-26 | ロバーツ リサーチ インスティテュート | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
| DE102004003572A1 (de) * | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| US20090035276A1 (en) * | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| WO2007143538A2 (en) * | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Pike-a enhances infection by myxoma virus |
| WO2007143548A2 (en) * | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| WO2012171007A2 (en) * | 2011-06-09 | 2012-12-13 | University Of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| US20190350992A1 (en) * | 2016-11-17 | 2019-11-21 | Vcn Biosciences Sl | Use of viral vectors in the treatment of retinoblastoma |
| EP3681998A1 (en) | 2017-09-11 | 2020-07-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Tumor organoid model |
| WO2019177438A1 (ko) * | 2018-03-16 | 2019-09-19 | 바이로큐어 주식회사 | 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용 |
| RU2699754C1 (ru) * | 2018-05-08 | 2019-09-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" | Флуоресцирующая клеточная линия глиомы и способ её получения |
| US12128099B2 (en) | 2018-05-25 | 2024-10-29 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US20210169957A1 (en) * | 2018-08-17 | 2021-06-10 | Virocure, Inc. | Combined use of squirrel poxvirus and myxoma poxvirus, for treating cancer |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| US12428626B2 (en) | 2018-11-20 | 2025-09-30 | Bioventures, Llc | Cells for the production of viruses and methods of using the same |
| US11591616B1 (en) | 2019-04-22 | 2023-02-28 | Colorado State University Research Foundation | Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| EP1003894A2 (en) | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| IL145899A0 (en) | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| AU6175000A (en) * | 1999-07-12 | 2001-01-30 | Viron Therapeutics, Inc. | Novel myxoma genes for immune modulation |
| JP4800924B2 (ja) * | 2003-03-07 | 2011-10-26 | ロバーツ リサーチ インスティテュート | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
| WO2007143545A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
-
2004
- 2004-03-08 JP JP2006504071A patent/JP4800924B2/ja not_active Expired - Fee Related
- 2004-03-08 AU AU2004216928A patent/AU2004216928C1/en not_active Ceased
- 2004-03-08 CA CA2517147A patent/CA2517147C/en not_active Expired - Fee Related
- 2004-03-08 EP EP04718235A patent/EP1601376B1/en not_active Expired - Lifetime
- 2004-03-08 WO PCT/CA2004/000341 patent/WO2004078206A1/en not_active Ceased
- 2004-03-08 MX MXPA05009526A patent/MXPA05009526A/es active IP Right Grant
- 2004-03-08 NZ NZ541951A patent/NZ541951A/en not_active IP Right Cessation
- 2004-03-08 US US10/547,859 patent/US7582614B2/en not_active Expired - Fee Related
- 2004-03-08 RU RU2005131020/15A patent/RU2362584C2/ru not_active IP Right Cessation
-
2005
- 2005-08-31 IL IL170601A patent/IL170601A/en unknown
- 2005-09-07 KR KR1020057016740A patent/KR101116858B1/ko not_active Expired - Fee Related
-
2009
- 2009-08-28 US US12/549,939 patent/US8227440B2/en not_active Expired - Fee Related
-
2011
- 2011-05-19 JP JP2011112835A patent/JP2011157399A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011157399A5 (https=) | ||
| Rodrigues et al. | Pathogenesis of cholangiocarcinoma | |
| Jiang et al. | The mechanisms of HBV-induced hepatocellular carcinoma | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| JP2020517715A5 (https=) | ||
| Thamrongwaranggoon et al. | Targeting hexokinase II as a possible therapy for cholangiocarcinoma | |
| CA2517147A1 (en) | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection | |
| Yuan et al. | The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions | |
| Javid et al. | The role of viruses in cancer development versus cancer therapy: an oncological perspective | |
| JP2014506233A5 (https=) | ||
| Zhao et al. | The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance | |
| JP2014523398A5 (https=) | ||
| Zhang et al. | Role of miRNA-122 in cancer | |
| Zou et al. | Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention | |
| JP2008531739A5 (https=) | ||
| Zhou et al. | Circular RNA-regulated autophagy is involved in cancer progression | |
| RU2007137008A (ru) | Применение комбинации вируса миксомы и рапамицина для терапевтического лечения | |
| CN101991579A (zh) | 熊果酸作为抗结肠肿瘤药物的应用 | |
| CN104069509A (zh) | Sr-b1作为鼻咽癌生物标记物及治疗靶点的应用 | |
| Saha et al. | Impact of anesthetics on oncogenic signaling network: a review on propofol and isoflurane | |
| Thakur et al. | Different chemosensitization approaches for the effective management of HNSCC | |
| CN103099809A (zh) | 一种治疗三阴性乳腺癌的药物组合物及其应用 | |
| Yang et al. | Liquiritin represses proliferation, migration and invasion of colorectal cancer cells through inhibition of the miR-671/HOXB3 signaling pathway | |
| Rathod et al. | Targeting the cGAS–STING Pathway in Gastrointestinal Cancers: Modulating Tumor-associated Inflammation for Therapeutic Effect |